Sydney Lupkin
People line up on Thursday for the first day of Clark County's pilot COVID-19 vaccination program at Cashman Center in Las Vegas. Ethan Miller/Getty Images hide caption
COVID-19 Supply Deal Lets Vaccine Maker Earmark Doses For Employees And Their Families
U.S. Government To Buy Additional 100 Million Doses Of Pfizer COVID-19 Vaccine
Pfizer, BioNTech Reach Deal To Supply U.S. With More Vaccine Doses
A worker passes through the security gate at the Moderna campus in Norwood, Mass., one of the sites where the biotechnology company is manufacturing its COVID-19 vaccine. Joseph Prezioso/AFP via Getty Images hide caption
If Pfizer Vaccine Is FDA Approved, What's Trump Administration's Plan For Buying It?
A vial of the COVID-19 vaccine developed by Pfizer and BioNTech that was used at the Royal Victoria Hospital in Belfast, U.K., on Tuesday. Liam McBurney/Bloomberg via Getty Images hide caption
Refrigerators store Pfizer's COVID-19 vaccine at a company facility in Kalamazoo, Mich. Jerica Pitts/AP hide caption
Novavax released its federal contract to develop and supply a COVID-19 vaccine. The agreement reveals terms that weren't previously known. Bloomberg via Getty Images hide caption
The Department of Health and Human Services on Saturday made public several contracts with companies working on COVID-19 vaccines as part of Operation Warp Speed. Mark Wilson/Getty Images hide caption
Regeneron has developed a drug called REGN-COV2 that is a combination of two monoclonal antibodies that block the virus that causes COVID-19. The company has a contract to supply up to 300 million doses to the U.S. government. Lev Radin/Pacific Press/LightRocket via Getty Images hide caption
Moncef Slaoui, a former GlaxoSmithKline executive, speaks during the kickoff announcement for Operation Warp Speed in the White House Rose Garden on May 15. Jabin Botsford/The Washington Post via Getty Images hide caption
After Months Of Questions, A Key Operation Warp Speed Adviser's Contract Emerges
A heavily redacted supply contract between the federal government and vaccine developer Moderna, headquartered in Cambridge, Mass., was released Friday. Joseph Prezioso/AFP via Getty Images hide caption
A panel of advisers to the Food And Drug Administration has raised questions about some aspects of the agency's approach to reviewing COVID-19 vaccines. Sarah Silbiger/Getty Images hide caption